Giovanni Caforio, Bristol Myers Squibb CEO (Pablo Martinez Monsivais/AP Images)
December 23, 2020 08:41 AM ESTUpdated 11:06 AM
Bioregnum
Opinion

The fi­nal hours and days are tick­ing away on a $6B bet as dead­line looms on a sus­pense­ful FDA de­ci­sion

The clock is tick­ing down to the year-end dead­line for an FDA ap­proval of liso-cel, and the sus­pense is killing in­vestors.

You’ll re­call that …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Com­pound­ed weight loss drugs have re­sult­ed in mis­dos­ing, hos­pi­tal­iza­tions, FDA warns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times